Atherosclerosis Drugs Market (Drug Class: Anti-platelet Medications, Cholesterol Lowering Medications, Fibric Acid and Omega-3 Fatty Acid Derivatives, Beta Blockers, Angiotensin-converting Enzyme (ACE) Inhibitors, Calcium Channel Blockers, Diuretics, Others; Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2030

Description

Atherosclerosis Drugs Market - Risk Associated with Cardiovascular Health to Drive Sales

Despite the prevalence of diabetes and cholesterol among a wide patient pool, the atherosclerosis drugs market will move at a sluggish CAGR of 2.5% during the forecast period, finds a recently published report by

This market growth is attributable to the high consumption of cholesterol-lowering drugs by patients to reduce blockages in arteries. A sedentary, yet, demanding lifestyle instigates consumers to opt for quick dietary choices, which will catalyze revenue streams to the atherosclerosis drugs landscape.

To add to that, government initiatives at a global level have played a crucial role in improving the quality of healthcare services and infrastructure, which has been encouraging pharmaceutical companies to develop effective drugs for the treatment of various diseases. The effectiveness of drugs coupled with their easy availability through streamlined distribution channels has been complementing the sales of atherosclerosis drugs. Analyzing the current and the future growth scope, the TMR study opines that, the atherosclerosis drugs market will register a value tantamount to ~US$ 57.4 Bn by 2027.

Popularity of Generic Drugs Poised to Overshadow Atherosclerosis Drugs Market Growth

In March 2019, the U.S. Food and Drug Administration approved a novel generic drug of Diovan to bridge the high demand and low supply gap of this critical drug, on account of multiple recalls of valsartan products manufactured by several brands. After two months, Zydus Cadila announced that it has received approval for Chlorthalidone, a generic version of Thalitone produced by Pfizer.

Get a glimpse of the in-depth analysis through our Report Brochure

These and many companies have scrambled towards the development of generic drugs to offer the near-same benefits of branded drugs at a low cost. The rapid rise in the penetration of generic drugs in parallel to increasing awareness among consumers about the cost benefits of these drugs is likely to curb the growth potential of the atherosclerosis drugs market.

Also, heart strokes and cardiovascular dysfunction are the symptoms associated with atherosclerosis conditions, which could lead to sudden death. On account of the severity of these symptoms, the survival rate is low among patients, which reduces the diagnosis percentage of atherosclerosis.

Distribution Partnerships with Retail Pharmacies Will Remain Beneficial

According to the statistical data of the TMR study, retail pharmacies will grow as the key point-of-sales channel for atherosclerosis drugs, as they are established at even the remotest of locations, thereby making it convenient for consumers to present prescriptions and purchase drugs. In addition, retail pharmacists offer a more consultative role regarding the route of administration and possible side effects of drugs. Retail pharmacies have the presence of several brands, which makes them a suitable purchase point for patients. However, hospital pharmacists operate in a more clinic-oriented manner by having significant contact with doctors and nurses, and they manage their inventories with only specific brands.

By 2027, players in the atherosclerosis drugs market can look at sales through retail pharmacies to a value tantamount to ~US$ 24 Bn.

Analysts’ Take on Atherosclerosis Drugs Market

Analyzing the impact of the drivers and restraints influencing the future of the atherosclerosis drugs market, analysts of the TMR study anticipate slow, yet, steady growth during the forecast period. While favorable government policies and impressive strides of the healthcare industry are projected to foster the leaps of the North American atherosclerosis drugs market, Asia Pacific will grow at an accelerated pace during the forecast period.

An investment made towards the development of novel drugs with a keen eye on their effectiveness will help in developing a weighted product portfolio. In addition, the convergence of e-Commerce and the healthcare sector will create high sales opportunities through online pharmacies for players operating in the atherosclerosis drugs market during the forecast period. 

Atherosclerosis Drugs Market: Overview

The atherosclerosis drugs market for the historical period of 2017-2018 and forecast period of 2019-2027, the rising prevalence of atherosclerosis and cardiovascular disease, and development of new treatments are anticipated to drive the global atherosclerosis drugs market during the period of forecast.

The global atherosclerosis drugs market was valued at ~US$ 45.7 Bn in 2018, and is expected to expand at a CAGR of 2.5% from 2019 to 2027.

As such, the global atherosclerosis drugs market is projected to be valued at ~US$ 57.4 Bn by the year 2027. 

Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases and Awareness About Cardiovascular Diseases: Key Drivers

Atherosclerosis is a leading cause of vascular diseases. For instance, according to the American Heart Association, Inc., the mortality rate of vascular disease is 700 per 100,000 people per year in the country.

Rise in the number of people with cardiovascular diseases is likely to fuel the growth of the global atherosclerosis drugs market. Obesity, unhealthy diets, and changes in lifestyles are factors leading to cardiovascular diseases. For instance, according to the American Heart Association, approximately 2,300 people died in 2018 and 92.1 million Americans are living with cardiovascular diseases.

According to an article published in NCBI, atherosclerosis accounted for more than 90% of cases of peripheral artery disease.

Rise in the level of low-density lipoproteins cholesterol (LDL-C) is directly associated with atherosclerosis.

According to the Centers for Diseases Control and Prevention, between 2005 and 2012, an estimated 29 million U.S. adults had elevated total cholesterol levels. Thus, the rising level of LDL-C is likely to boost the growth of the atherosclerosis drugs market.

Increase in incidences of cardiac arrests, heart failures, and other cardiovascular diseases have driven people to become more aware of heart failure warning signals and the importance of prompt response.

Government participation has also played an important role in raising concerns and creating awareness about cardiovascular disease treatment.

In 2015-2016, the American Heart Association committed to funding 980 new research projects worth over US$ 163 Mn. The organization uses donations to fund research projects. The American Heart Association funds more research on cardiovascular diseases and stroke than any organization, except for the Federal Government.

Increase in awareness about cardiovascular diseases and atherosclerosis in developing regions is anticipated to drive the atherosclerosis drugs market. For instance, the incidence of cardiometabolic diseases, such as metabolic syndrome, abnormal obesity, hypertension, ischemic heart diseases, stroke, and diabetes, is high in South Asian countries; hence, in 1993, a professional society was started at the University of Minnesota. This society organizes a conference on the topic of atherosclerosis and thrombosis every year in India. 

Atherosclerosis Drugs Market: Development of New Treatments

Key players in the global atherosclerosis drugs market are engaged in research and development to introduce new atherosclerosis drugs.

Rise in the prevalence and incidence of cardiovascular conditions due to plaque formation is leading to an increase in the demand for new treatment options.

E-selectin-targeting polymer is a new polymer developed by Ben-Gurion University (BGU) and the Sheba Medical Center. It is a new therapy for atherosclerosis that reduces the risk of ischemia, stroke, arterial thrombosis, and myocardial infraction, by reducing and preventing plaque formation.

Protein Convertase Subtilisin/Kexin type 9 (PCSK 9) is an intensive statin therapy to decrease the low density lipoprotein cholesterol level, which reduces the risk of coronary atherosclerotic plaque formation.

New treatments for atherosclerosis are likely to fuel the growth of the global atherosclerosis drugs market.

Availability of Generic Drugs Hampers Atherosclerosis Drugs Market

The launch of new generic products for the treatment of atherosclerosis is hampering the global atherosclerosis drugs market.

In March 2019, the U.S. Food and Drug Administration approved a new generic of Diovan (Valsartan). Valsartan is an angiotensin II receptor blocker used in the treatment of high blood pressure and heart failure.

In October 2015, Mylan Pharmaceuticals Inc., a subsidiary of Mylan Inc., received approval from the U.S. Food and Drug Administration for the generic version of Hyzaar tablets.

Global Atherosclerosis Drugs Market: Competition Landscape

This report profiles major players in the global atherosclerosis drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

The atherosclerosis drugs market is moderately fragmented, with the presence of a few large-scale players present in international markets and numerous small-scale players in regional markets. The top four to five players hold a majority share of the global atherosclerosis drugs market.

Prominent players operating in the global atherosclerosis drugs market include:

  • GlaxoSmithKline Plc
  • Sanofi, F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Novartis AG
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp)
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  • Mylan N.V., Amgen Inc.
  • Pfizer, Inc. 

Key Questions Answered in the Atherosclerosis Drugs Market Report 

  • What is the scope of growth of product companies in the atherosclerosis treatment sector?
  • What will be the Y-o-Y growth of the atherosclerosis drugs market between 2019 and 2027?
  • What is the influence of the changing trends in technologies on the global atherosclerosis drugs market?
  • Will North America continue to remain the most profitable regional market for atherosclerosis drug providers?
  • Which factors will impede the growth of the global atherosclerosis drugs market during the forecast period?
  • Which are the leading companies in the global atherosclerosis drugs market? 

Global Atherosclerosis Drugs Market – Segmentation

Drug Class

  • Anti-platelet Medications
  • Cholesterol Lowering Medications
  • Fibric Acid and Omega-3 Fatty Acid Derivatives
  • Beta Blockers
  • Angiotensin-converting Enzyme (ACE) Inhibitors
  • Calcium Channel Blockers
  • Diuretics
  • Others

Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Atherosclerosis Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

            4.3.1.1. Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases 

            4.3.1.2. Development of New Treatments 

            4.3.1.3. Rising Awareness about Cardiovascular Diseases 

        4.3.2. Restraints

            4.3.2.1.  Availability of Generic Products

            4.3.2.2.  Low Diagnostic Rate 

        4.3.3. Opportunities

    4.4. Global Atherosclerosis Drugs Market Analysis and Forecast, 2017–2027

5. Market Outlook

    5.1. Clinical Trial Pipeline Analysis

    5.2. Disease Prevalence & Incidence Rate globally with key countries

    5.3. Brand Analysis

6. Global Atherosclerosis Drugs Market Analysis and Forecast, By Drug Class 

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        6.2.1. Anti-platelet Medications

        6.2.2. Cholesterol Lowering Medications

        6.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        6.2.4. Beta Blockers

        6.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        6.2.6. Calcium Channel Blockers

        6.2.7. Diuretics

        6.2.8. Others

    6.3. Global Atherosclerosis Drugs Market Attractiveness, by Drug Class 

7. Global Atherosclerosis Drugs Market Analysis and Forecast, By Distribution Channel 

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        7.2.1. Retail Pharmacies

        7.2.2. Hospital Pharmacies

        7.2.3. Online Pharmacies 

    7.3. Global Atherosclerosis Drugs Market Attractiveness, by Distribution Channel 

8. Global Atherosclerosis Drugs Market Analysis and Forecast, By Region

    8.1. Key Findings

    8.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Region 

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Global Atherosclerosis Drugs Market Attractiveness, by region 

9. North America Atherosclerosis Drugs Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        9.2.1. Anti-platelet Medications

        9.2.2. Cholesterol Lowering Medications

        9.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        9.2.4. Beta Blockers

        9.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        9.2.6. Calcium Channel Blockers

        9.2.7. Diuretics

        9.2.8. Others

    9.3. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        9.3.1. Retail Pharmacies

        9.3.2. Hospital Pharmacies

        9.3.3. Online Pharmacies 

    9.4. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Atherosclerosis Drugs Market Attractiveness

        9.5.1. By Drug Type 

        9.5.2. By Distribution Channel 

        9.5.3. By Country

10. Europe Atherosclerosis Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        10.2.1. Anti-platelet Medications

        10.2.2. Cholesterol Lowering Medications

        10.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        10.2.4. Beta Blockers

        10.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        10.2.6. Calcium Channel Blockers

        10.2.7. Diuretics

        10.2.8. Others

    10.3. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        10.3.1. Retail Pharmacies

        10.3.2. Hospital Pharmacies

        10.3.3. Online Pharmacies 

    10.4. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country Sub/region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Europe Atherosclerosis Drugs Market Attractiveness

        10.5.1. By Drug Type 

        10.5.2. By Distribution Channel 

        10.5.3. By Country/Sub-region

11. Asia Pacific  Atherosclerosis Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        11.2.1. Anti-platelet Medications

        11.2.2. Cholesterol lowering medications

        11.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        11.2.4. Beta blockers

        11.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        11.2.6. Calcium Channel Blockers

        11.2.7. Diuretics

        11.2.8. Others

    11.3. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        11.3.1. Retail Pharmacies

        11.3.2. Hospital Pharmacies

        11.3.3. Online Pharmacies 

    11.4. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Atherosclerosis Drugs Market Attractiveness

        11.5.1. By Drug Type 

        11.5.2. By Distribution Channel 

        11.5.3. By Country/Sub-region

12. Latin America Atherosclerosis Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        12.2.1. Anti-platelet Medications

        12.2.2. Cholesterol Lowering Medications

        12.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        12.2.4. Beta blockers

        12.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        12.2.6. Calcium Channel Blockers

        12.2.7. Diuretics

        12.2.8. Others

    12.3. Latin America  Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        12.3.1. Retail Pharmacies

        12.3.2. Hospital Pharmacies

        12.3.3. Online Pharmacies 

    12.4. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Atherosclerosis Drugs Market Attractiveness

        12.5.1. By Drug Type 

        12.5.2. By Distribution Channel 

        12.5.3. By Country/Sub-region

13. Middle East & Africa  Atherosclerosis Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        13.2.1. Anti-platelet medications

        13.2.2. Cholesterol Lowering Medications

        13.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        13.2.4. Beta blockers

        13.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        13.2.6. Calcium Channel Blockers

        13.2.7. Diuretics

        13.2.8. Others

    13.3. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        13.3.1. Retail Pharmacies

        13.3.2. Hospital Pharmacies

        13.3.3. Online Pharmacies 

    13.4. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC 

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Atherosclerosis Drugs Market Attractiveness

        13.5.1. By Drug Type 

        13.5.2. By Distribution Channel 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1.   Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Key Company’s Market Ranking Analysis

    14.3. Company Profiles

        14.3.1. GlaxoSmithKline Plc

            14.3.1.1. Company Overview

            14.3.1.2. Company Financials

            14.3.1.3. Growth Strategies

            14.3.1.4. SWOT Analysis

        14.3.2. Sanofi

            14.3.2.1. Company Overview

            14.3.2.2. Company Financials

            14.3.2.3. Growth Strategies

            14.3.2.4. SWOT Analysis

        14.3.3. Hoffmann-La Roche Ltd

            14.3.3.1. Company Overview

            14.3.3.2. Company Financials

            14.3.3.3. Growth Strategies

            14.3.3.4. SWOT Analysis

        14.3.4. Bayer AG

            14.3.4.1. Company Overview

            14.3.4.2. Company Financials

            14.3.4.3. Growth Strategies

            14.3.4.4. SWOT Analysis

        14.3.5. Novartis AG

            14.3.5.1. Company Overview

            14.3.5.2. Company Financials

            14.3.5.3. Growth Strategies

            14.3.5.4. SWOT Analysis

        14.3.6. Merck & Co., Inc. (Merck Sharp & Dohme Corp)

            14.3.6.1. Company Overview

            14.3.6.2. Company Financials

            14.3.6.3. Growth Strategies

            14.3.6.4. SWOT Analysis

        14.3.7. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

            14.3.7.1. Company Overview

            14.3.7.2. Company Financials

            14.3.7.3. Growth Strategies

            14.3.7.4. SWOT Analysis

        14.3.8. Mylan N.V. 

            14.3.8.1. Company Overview

            14.3.8.2. Company Financials

            14.3.8.3. Growth Strategies

            14.3.8.4. SWOT Analysis

        14.3.9. Amgen Inc.

            14.3.9.1. Company Overview

            14.3.9.2. Company Financials

            14.3.9.3. Growth Strategies

            14.3.9.4. SWOT Analysis

        14.3.10. Pfizer, Inc.

            14.3.10.1. Company Overview

            14.3.10.2. Company Financials

            14.3.10.3. Growth Strategies

            14.3.10.4. SWOT Analysis

Choose License Type

Checkout Inquiry Sample